Abstract: A pharmaceutical formulation having immunomodulating and regenerating effect on abnormal function of cell tissue division-regulating system comprises, as an active ingredient, mercury dichloride or potassium arsenite or sodium arsenate in the amount of 0.01-1.5% by weight and of a diluent up to 100% by weight. The proposed pharmaceutical formulation preferably contains natural white grape wine with sugar content of 3-4% by weight or whey with sugar content of 3-4% by weight as the diluent.

Abstract: The present invention discloses a preventive or ameliorant of hypertension or medical symptoms caused by it and a food or beverage that prevents or ameliorates hypertension or medical symptoms caused by it that contain for its active ingredient dioxabicyclo?3.3.0!octane derivative represented by the formula (2). ##STR1## wherein, R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5 and R.sup.6 are respectively and independently a hydrogen atom or an alkyl group having 1 to 3 carbon atoms, or R.sup.1 and R.sup.2 and/or R.sup.4 and R.sup.5 collectively represent a methylene group or ethylene group, and n, m and L represent 0 or 1.

Abstract: A method and product for treating and preventing diarrhea and scours is provided. The method involves treating a subject who has diarrhea, or scours, or is at risk of getting diarrhea or scours with an aromatic compound of the invention. The products of the invention are a veterinary preparation of the aromatic compound of the invention and an anti-scours agent, and a pharmaceutical preparation of the aromatic compound of the invention and an anti-diarrheal agent.

Abstract: A method is provided for lowering serum lipids, cholesterol and/or triglycerides and thereby inhibiting atherosclerosis by administering to a patient an MTP inhibitor, in combination with a cholesterol lowering drug, such as pravastatin.

Abstract: The present invention relates to the use of a non-ionic surface-active agent or an emulsion for the reduction of the hemolytic effects of an amphiphilic compound. There is also provided a method for reducing the hemolytic effects of an amphiphilic compound which comprises formulating said compound with a non-ionic surface-active agent or in the form of an emulsion.

Abstract: A method for treatment of gastric acid related diseases by inhibition of gastric acid secretion comprising administering to a mammal in need of treatment a therapeutically effective amount of the (-)-enantiomer of 5-methoxy-2-??(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl!sulfinyl!-1H-benz imidazole or a pharmaceutically acceptable salt thereof, so as to effect decreased interindividual variation in plasma levels upon administration. The use of the (-)-enantiomer of omeprazole to receive increased average plasma levels (AUC) upon administration of the same doses of the (-)-enantiomer of omeprazole compared to those of racemic omeprazole is also claimed, as well as an improved antisecretory effect and a better clinical effect.

Abstract: Compounds for treating or preventing cerebrovascular diseases are disclosed. These compounds are 5-HT antagonists. More specifically, these compounds, when combined with pharmaceutically acceptable carriers or excipients and administered to animals including humans, are useful in treating or preventing cerebrovascular dementia.

Abstract: Disclosed are methods and compositions for reducing coronary artery stenosis, restoring blood flow to infarcted myocardium, improving myocardial perfusion, reducing heart attacks or other adverse cardiovascular events, or treating symptoms of inadequate myocardial function in a mammal involving administering to the mammal (a) a compound that includes eicosapentaeneoic acid or docosahexaeneoic acid and (b) a cholesterol-lowering therapeutic, combined with dietary restrictions (resulting in aggressive loading of marine lipids), whereby a serum LDL concentration of less than 75 mg/dl (and preferably less than 55 mg/dl) is achieved. One particular method involves administering to the mammal a combination that includes (a) a compound that includes an eicosapentaeneoic or docosahexaeneoic acid (for example, a marine lipid) and (b) a cholesterol synthesis or transfer inhibitor, and which may also optionally include aspirin and/or niacin.

Abstract: Male menopause is characterized by significant decreases in serum levels of bioavailable androgens. The administration of aromatase inhibitors to men experiencing male menopause can remedy the relative androgen deficiency in men while at the same time approximating the physiological hormonal ratio of androgens to estrogens.

Abstract: Combinations of a sulfonylurea antidiabetic agent and a glitazone antidiabetic agent are useful for treating diabetes mellitus and improving glycemic control.

Abstract: A hormone replenishment method particularly useful in maintaining the body's neuroendocrine clock at optimal levels and combating conditions associated with advancing age is disclosed. The method includes determining that the level of human growth hormone and at least two other supplemental hormones are below optimal or pre-determined physiological levels for an adult human. Once it has been established that the level of human growth hormone and at least two of certain supplemental hormones are below pre-determined physiological levels, the method includes establishing a regimen for the replenishment of the level of the deficient hormones to optimal or pre-determined physiological levels. The supplements hormones include the sex hormones, namely testosterone, progesterone, and estrogen, the pineal hormone melatonin, the adrenal hormones, namely DHEA and pregnenolone, the thyroid hormone, and the thymus hormone.

Abstract: Compounds of the formula I ##STR1## where one of the radicals R.sup.1 and R.sup.3 is a radical of the formula II --(CH.sub.2).sub.n --A--CH.sub.3 (II) in which A is a covalent bond, --C(O)-- or --C(R.sup.4)(OH)--, are suitable for the production of pharmaceuticals for the modulation of apoptosis. A combination preparation comprising a compound of the formula I and a compound of the formula IV and/or V ##STR2## is suitable for the production of pharmaceuticals for the modulation of apoptosis.

Abstract: The present invention provides a preparation for percutaneous absorption comprising as an effective component a prostaglandin I.sub.2 derivative and a fatty acid or a derivative thereof, or a mixture of two or more of these, which has high percutaneous permeability of the PGI.sub.2 derivative. Particularly, the present invention provides a preparation for percutaneous absorption comprising 5,6,7-trinor-4,8-inter-m-phenylene PGI.sub.2 derivative and a C.sub.6 -C.sub.24 fatty acid, a salt thereof or an ester thereof, or a mixture of two or more of these, which has high percutaneous permeability of the PGI.sub.2 derivative. This preparation for percutaneous absorption suggests a possibility to last pharmacological effects and to reduce side effects. Thus, the preparation is expected to be used for therapy of various diseases, aiming at topical and systemic actions.

Abstract: Use of at least one polymer or one biopolymer, called HBGFPPs, specifically protecting the growth factors of families of FGFs and beta TGFs from tryptic degradation and not significantly inhibiting coagulation, in the manufacture of a drug for the treatment of lesions of the digestive tract and of primary or secondary derived tissues of the endoderm and the mesoderm.

Abstract: The use of the compound I ##STR1## or its pharmaceutically utilizable salts for the propylaxis and treatment of the squelae of chronic reduced cerebral blood supply, in particular of stroke, and for the treatment of nuerodegenerative disorders is claimed.

Abstract: A hypercholesterolemia therapeutic agent containing lycopene as an effective ingredient. The hypercholesterolemia therapeutic agent comprises a soft-capsulated drug, and the soft-capsulated drug comprises a soft capsule which comprises gelatin and glycerin, and contents which comprise lycopene, .beta.-carotene, .alpha.-carotene, d-.alpha. tocopherol and a mixture of a wheat germ oil and a vegetable oil, which contents are packed into the soft capsule.

Abstract: The use of the compound I ##STR1## or its pharmaceutically utilizable salts for the propylaxis and treatment of the sequel of chronic reduced cerebral blood supply, in particular of stroke, and for the treatment of neurodegenerative disorders is claimed.

Abstract: A pharmaceutical aerosol formulation which comprises particulate medicament, a fluorocarbon of hydrogen-containing chlorofluorocarbon propellant and a surfactant of general formula (I), wherein n is an integer of 1 to 18; m is an integer of 0 to 17; and R.sup.1, R.sup.2 and R.sup.3 are each independently a hydrogen atom or a C.sub.1-4 alkyl group.

Abstract: Magnesium is formulated in combination with vitamin E, vitamin C, folate, selenium, and optionally melatonin in a unit dosage form for oral administration, for the treatment of vasoconstriction and the physiological and pathological conditions giving rise to vasoconstriction. These active agents complement each other in suppressing these conditions, using a variety of mechanisms operating in conjunction with one another. The inclusion of magnesium in a plurality of forms provides additional advantages in terms of controlling and sustaining the release of magnesium in locations along the digestive tract where the magnesium will have its greatest effectiveness as a therapeutic agent, thus improving control over thge clinical bioavailability of magnesium and in improving the selection of appropriate therapeutic ranges.

Abstract: This invention provides methods of inhibiting pulmonary hypertensive disease which comprise administering to a mammal in need thereof a compound having activity as a tachykinin receptor antagonist.